Brind.

A study is underway evaluating the combination of petosemtamab with Merck's Keytruda, assessing efficacy across various CPS levels.

1 report, 1 independent Updated Jul 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

BAYER Merck CPSLiger

Keep exploring

The entities involved

BAYER
company in Prague, Czechia
- Bayer acquired Monsanto and its Roundup product line. The company now faces lawsuits regarding the product's liability.Sun 23:14
- Bayer is supplying canola feedstock to Neste to jointly scale winter canola for biofuels.Sun 16:16
Merck
public company in Indonesia
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13
CPS
Seasonal Malaria Chemotherapy
- CPS seeks city council approval for a property sale.Fri 05:15

Related events

Moderna and Merck are developing a combination therapy using Keytruda.Aug 19

Coverage

Newest first; wire copies grouped

Jul 11ZacksMRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success Merus N.V. MRUS shares have jumped 29.9% over the past three months. The uptrend was fueled by encouraging interim results from a